Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014

摘要: Chemotherapy currently has an established role in the treatment of hormonerefractory prostate cancer. There is strong evidence that combined-modality treatment, using androgen ablation addition to radiotherapy, provides a benefit above and beyond radiotherapy alone patients with poor prognosis, perhaps due effect on subclinical distant disease. Several clinical trials under way are investigating whether chemotherapy known efficacy hormone-refractory setting can provide survival advantage when used adjuvantly.